Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737784 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
A Phase 1 study of Epilepsy and SCN2A-DEE, sponsored by Praxis Precision Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT05737784 is a Phase 1 study of Epilepsy and SCN2A-DEE that is actively recruiting participants, run by Praxis Precision Medicines. The registered enrollment target is 60 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05737784, a Phase 1 study of Epilepsy and SCN2A-DEE, is actively recruiting participants, sponsored by Praxis Precision Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Interventions
- DRUG PRAX-222 - Initial Dose
- DRUG PRAX-222 - Initial Ascending Doses
- DRUG PRAX-222 - Optional Ascending Doses
- DRUG PRAX-222 - Fixed Doses
- PROCEDURE Placebo
Study Locations (3)
Tennessee
- Le Bonheur Childrens Hospital - Memphis
Rio Grande do Sul
- Hospital de Clinicas de Porto Alegre - Porto Alegre
Other
- Praxis Research Site - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05737784
The ClinicalTrials.gov registry entry for NCT05737784 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The listed sponsor is Praxis Precision Medicines, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 5 interventions - of which PRAX-222 - Initial Dose is the first listed.
NCT05737784 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, Rio Grande do Sul, Other.
Frequently Asked Questions
What is clinical trial NCT05737784 about?
NCT05737784 is a clinical study titled "A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy". The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
What is the current status of trial NCT05737784?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-04-13. Estimated completion is 2027-09.
What conditions does trial NCT05737784 study?
This clinical trial studies the following conditions: Epilepsy, SCN2A-DEE.
What interventions are being tested in trial NCT05737784?
The interventions under investigation include: PRAX-222 - Initial Dose (DRUG), PRAX-222 - Initial Ascending Doses (DRUG), PRAX-222 - Optional Ascending Doses (DRUG), PRAX-222 - Fixed Doses (DRUG), Placebo (PROCEDURE).
Who is sponsoring clinical trial NCT05737784?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05737784 being conducted?
This trial has 3 study locations across Tennessee, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
-
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.